The dramatic global health emergency due to the SARS-CoV-2 pandemic requires new diagnostic devices capable of identifying the presence of virus particles in patient biological samples. In this direction, the development of an innovative low-cost test, which provides the result within a few minutes, which is reproducible and which can reveal the direct presence of even a few viral particles, would be of fundamental importance for the monitoring and containment of the pandemic.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 15 of 17
The assessment of bio-humoral markers beyond clinical evaluation would allow a more comprehensive pheno/endotyping of patients affected by chronic inflammatory diseases. Therapy personalization would require a profile of the mediators that are relevant in the disease pathogenesis and that well correlate with prognosis. Currently, the measurement of multiple biomarkers is not included in patient evaluation because it has high costs, requires centralized laboratories, experienced personnel and bulky equipment and is time-consuming.
The portable device is intended to assess exposure to electromagnetic fields produced by an MRI equipment. The device (dosimeter) allows to improve the analysis and study of the problems related to the exposure of the operators, starting from the technical-scientific aspects related to the exposure, also allowing to create a manual of best practices as well as to improve the professional training of operators.
Silicon nanowires (SiNWs) are 1D structures with diameter ranging from few tens to hundreds of nanometers and length varying from few tens of nanometers to millimiters. SiNWs are fabricated in the labs of the IMM-CNR, Rome Unit, by using bottom-up technologies such as plasma enhanced chemical vapor deposition (PECVD) at low growth temperature ((≤350°C), allowing the use of plastic and glassy substrates. Their electrical properties can be tuned by controlling the p/n doping during the growth.
Detection devices for the presence of molecules of interest (analytes) enjoyed a renewed burst with the introduction of biological components (biosensors). Their high specificity is often used in various fields, from environmental monitoring and biomedicine to the protection and promotion of agri-food products. However, the high cost of production and the lack of compatibility with mass sampling (high-throughput) sometimes limit their use.
Integrative omics has posed new challenges in modern precision medicine, particularly in oncology, including i) the identification of new tumor markers for early, precise, and non-invasive diagnostics, and ii) the discovery of innovative molecular targets for therapeutic applications. Our studies on medulloblastoma, a highly malignant childhood tumor, have contributed to identifying RNA molecules that meet these criteria.
In our recent publication we identified a group of bladder cancer-specific ncRNA, called T-UCRs that are the most up-regulated in bladder cancer patient samples compared with normal bladder urothelium.
An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.
We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.
Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.
Severe asthma or chronic obstructive pulmonary disease (COPD) are nowadays associated with a poor response to corticosteroids which led to the use of high-dose with consequent improved onset of side effects. The use of nanotechnologies can represent an innovative approach for the effective treatment of both asthma and COPD. The development of new nano-formulations involving the use of nanomaterials and specifically tailored to be inhaled offers numerous advantages over conventional inhaled dosage forms.
The study of proteins is typically limited to notions, sometimes with the aid of virtual 3D models, obtained from visualization programs. A knowledge of this type, although useful, limits the ability to acquire a more direct knowledge, almost never leads to awareness of dimensions, and is particularly difficult for those who do not have a strong capacity for three-dimensional imagination.
The proposed technology is about the development of an innovative sunscreen obtained from cod fish bones, according to the principles of the circular economy. The sunscreen is a reddish powder, which is constituted of hydroxyapatite (a calcium phosphate main component of human bones) modified with iron. It is prepared with a simple and easily scalable process (treatment of the bones in Fe solution and successively at T = 700 oC) and could be adapted for bones of other fishes.
EXPO is a software for the determination of the atomic structure of various materials (organic, metallorganic, inorganic), available in the form of microcrystalline powders, in order to derive the structure-property relationships. EXPO requires the molecular formula of the material, the experimental X-ray diffraction data and, in some cases, the expected molecular geometry.
QUALX is a software for qualitative and semi-quantitative phase analysis of materials (organic, metallorganic, inorganic), available in the form of microcrystalline powders. It uses a database distributed together with the software. QUALX identifies the crystalline chemical phase, one or more of than one, present in a material and determines approximately the weight percentages of each phase present in a mixture.